YY1 is a novel potential therapeutic target for the treatment of HPV infection-induced cervical cancer by arsenic trioxide.

Guifen He,Qian Wang,Yuqi Zhou,Xiaohua Wu,Lan Wang,Nadire Duru,Xiangtao Kong,Pingzhao Zhang,Bo Wan,Long Sui,Qisang Guo,Jian-Jian Li,Long Yu
DOI: https://doi.org/10.1097/IGC.0b013e31821d2525
2011-01-01
International Journal of Gynecological Cancer
Abstract:These results demonstrated that the expression of YY1 is upregulated in cervical carcinomas and that YY1 plays a critical role in the progression of HPV-positive cervical cancer. In addition, YY1 inhibition induces p53 activation and apoptosis in HPV-infected HeLa cells. Thus, YY1 is an As2O3 target and could serve as a potential drug sensitizer for anti-cervical cancer therapy.
What problem does this paper attempt to address?